Clinical Study

Increased Production of Interleukin-4, Interleukin-10, and Granulocyte-Macrophage Colony-Stimulating Factor by Type 2 Diabetes' Mononuclear Cells Infected with Dengue Virus, but Not Increased Intracellular Viral Multiplication

Ing-Kit Lee,^{1,2,3} Ching-Jung Hsieh,⁴ Rong-Fu Chen,⁵ Zih-Syuan Yang,⁶ Lin Wang,⁷ Chang-Mei Chen,³ Chiung-Fen Liu,³ Chung-Hao Huang,⁸ Chun-Yu Lin,^{8,9} Yen-Hsu Chen,^{8,9} Kuender D Yang,⁵ and Jien-Wei Liu^{1,2,3}

¹ Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan

² Chang Gung University Medical College, Tao-Yuan 333, Taiwan

³ Infection Control Committee, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan

⁴ Division of Endocrinology & Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan

⁵ Department of Medical Research, Show Chwan Memorial Hospital, Changhua 500, Taiwan

⁶ Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan

⁷ Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan

⁸ Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital,

Kaohsiung Medical University, Kaohsiung 807, Taiwan

⁹ Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan

Correspondence should be addressed to Jien-Wei Liu; jwliu@cgmh.org.tw

Received 9 May 2013; Revised 3 July 2013; Accepted 5 July 2013

Academic Editor: Patrizia Bagnarelli

Copyright © 2013 Ing-Kit Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

It has been reported that diabetes mellitus (DM) was an epidemiologically identified risk factor for development of dengue hemorrhagic fever (DHF)/severe dengue in dengue virus (DENV) affected patients, and T helper 2 (Th2) cytokines such as interleukin-4 (IL-4) and IL-10 each plays an important role in the immunopathogenesis of DHF in studies involving general population. To better understand the relationship between these epidemiological and immunological findings, we performed an *in vitro* study evaluating the sequential immunological reactions and viral load in the DENV infected mononuclear cells of adults with type 2 DM (T2DM group, n = 33) and normal adults (control group, n = 29). We found in the T2DM group significantly higher IL-4 level on the first (P = 0.049) and the third (P = 0.022) postinfection days, while higher IL-10 (P = 0.042) and granulocyte-macrophage colony-stimulating factor (GM-CSF) (P = 0.009) were detected on the third postinfection day. No significant difference in DENV viral load between the cultured mononuclear cells from both groups was found on the first and third post-infection days. These data immunologically suggest that patients with T2DM are at higher risk for development of DHF/severe dengue and strengthen the previously epidemiologically identified role of DM being a predictive risk factor for progressing into DHF/severe dengue in DENV-affected patients.

1. Introduction

Dengue is a major medical and public health problem in tropical and subtropical regions. It is estimated that approximately 50 million dengue episodes occur over the globe annually, and more than 2.5 billion people are living in geographic locales where dengue is endemic [1, 2]. There are four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4)

[1, 2], and patients infected by any of the DENV serotypes may be asymptomatic or develop a wide array of clinical symptoms/signs ranging from a nonspecific febrile illness, dengue fever (DF) to dengue hemorrhagic fever (DHF). DHF is clinically characterized by bleeding and plasma leak, and a severe DHF leads to hypovolemia and even circulatory collapse in the affected patient, which is known as dengue shock syndrome (DSS) [1, 2]. Well-documented risk factors for DHF include secondary infection caused by a DENV serotype which differs from that responsible for the prior dengue episode [3, 4], the genetic predilection for causing hemorrhage of the culprit DENV [5, 6], the genetic predisposing for hemorrhage of the dengue patient [7], the aging of the host [8, 9], and diabetes mellitus (DM) [10-13]. DM is a multifaceted disease that implicates metabolic derangements and immune dysfunction [14]. The frequently found comorbidities in diabetic patients such as cardiovascular and chronic kidney diseases may add to the altered host responses to infection and clinical outcomes [15, 16]. The immunologic responses of DM patients when suffering from DENV infection have not been fully understood. It was documented that T helper (Th) cells play an important role in the immunopathogenesis of DHF [17]. Based on the types of cytokine production at activation, Th cells are divided into Th1 and Th2 [18, 19]. Activated Th1 produces IFN-y, IL-2, and IL-12, whereas Th2 produces IL-4, IL-5, IL-10, and IL-13 [18, 19]. Of note, the immunologic responses in a progressive dengue patient were reported to involve a shift from the activated Th1-type cytokine response in DF to the activated Th2-type cytokine response in DHF [17, 20-24]. In general, serum levels of IFN-y and IL-2 are high in patients suffering from DF, while those of IL-4, IL-6, and IL-10 remarkably upsurge in hosts experiencing severe DHF [17, 20-24]. To better understand the immune responses in dengue individuals with type 2 DM (T2DM), we investigated Th1/Th2 reactions by DENV-infected mononuclear cells of T2DM individuals. The implications of the results will be discussed.

2. Material and Methods

2.1. Ethics Statement. This study was conducted with an informed consent from all participants, which was approved by the Institutional Review Board of Chang Gung Memorial Hospital (Document no. 98-2957B).

2.2. Study Period and Blood Sampling. The study was conducted at Kaohsiung Chang Gung Memorial Hospital, a 2700-bed medical facility serving as a primary care and tertiary referral centre in southern Taiwan, from March through December in 2010. Participants included those with a T2DM and healthy adults, aged between 50 and 60 years. Individuals with T2DM referred to those who have been taking oral hypoglycemic agent(s) for a previously diagnosed DM [14]. Blood specimens sampled from T2DM and healthy individuals were allocated to the study group and the control group, respectively. Eight milliliters of blood were sampled from each participant. The whole blood was immediately separated into plasma and blood cells (i.e., leukocytes and erythrocytes) by centrifugation at 2,500 rpm (150 \times g) for 20 minutes. Plasma was dispensed into several aliquots and kept frozen at -80° C until being used.

2.3. Determination of Past DENV Infection. The serum samples of all participants were tested for dengue virus-specific immunoglobulin M (IgM) and G (IgG) antibodies using a dengue blot detection kit (Gene Labs Diagnostics, Singapore) [25, 26].

2.4. Separation of Mononuclear Cells. Leukocytes were separated from erythrocytes by 4.5% dextran sedimentation. After removal of erythrocytes, leukocytes were further separated into mononuclear cells and polymorphonuclear cells by density gradient centrifugation (350 g/30 min in Ficoll-Paque PLUS, Amersham Biosciences Corp.) according to standard procedures as described elsewhere [26]. Mononuclear cells were suspended in supplemented RPMI 1640 medium (Gibco BRL, Gaithersburg, MD, USA) to yield a final concentration of 1.0×10^6 cells/mL for studies.

2.5. Preparation of DENV-2. DENV-2 (New Guinea C strain) obtained from the Institute of Preventive Medicine, National Defense Medical Center, Taiwan, was propagated in *Aedes albopictus* C6/36 cells as previously described [27] and was used in this study. The DENV-2 viruses were harvested from the C6/36 mosquito cell-culture supernatants after incubation for 5 days. The DENV-2 titers in the supernatants were measured by a standard plaque-forming unit (pfu) assay on baby hamster kidney-21 cells. The virus titers were adjusted to a concentration of 5.0×10^6 pfu/mL in RPMI 1640 medium for studies.

2.6. DENV-2 Infection of Mononuclear Cells. A prior report on multiplicity of infection (MOI) of DENV ranging from 1 to 10 suggested that the higher the MOI, the simultaneously increased the DENV infection and apoptosis in the inoculated mononuclear cells [28]. To achieve a yield of sufficient DENV-infected mononuclear cells while avoiding excessive cellular apoptosis, in this experiment we used the MOI of 5, which was proven appropriate previously [29, 30]. Specifically, mononuclear cells were seeded at a density of 1.0×10^6 cells/mL on 24-well plates. After an overnight incubation, the mononuclear cells were inoculated with DENV-2 from the stock with the MOI of 5 at 37°C for 2 hours [26]. The mononuclear cells were then washed twice in phosphate-buffered saline to remove cell-free viruses, and complete RPMI 1640 medium supplemented with 10% fetal bovine serum was added into each well. The infected cells were cultured in complete RPMI 1640 medium at 37°C in a 5% CO₂ incubator. To demonstrate the innate and adaptive immunity responses in vitro, the supernatants and cells were harvested and analyzed on the first and third postinfection days, respectively, for measurement of responsive immune mediators and viral loads.

2.7. Measurement of TNF- α , IL-2, IL-4, IL-10, IL-12, GM-CSF, and MCP-1 Levels. In this study, the innate mediator was

demonstrated by TNF- α [31], the Th1/Th2 reaction by IL-2, IL-4, IL-10, and IL-12 levels [19], vascular leakage mediator by MCP-1 level [32], and activated leukocytes-derived growth factor by the GM-CSF level [33]. The concentrations of TNF- α , IL-2, IL-4, IL-10, IL-4, GM-CSF, and MCP-1 in the supernatants from the infected mononuclear cells were measured using the FlowMetrix System (Luminex Corporation, Austin, TX, USA) according to the manufacturer's instructions [34].

2.8. Quantitation of Viral Load by Reverse Transcription-Polymerase Chain Reaction (RT-PCR). Viral RNA was extracted from cultured mononuclear cells to assess DENV-2 RNA viral copies by quantitative RT-PCR, as previously described [24]. The forward primer, reverse primer, and nested fluorescent probe sequences for detecting DENV-2 were 50-GGCTTAGCGCTCACATCCA-30, 50-GCTGGCCACCCT-CTCTTCTT-30, and FAM-50-CGCCCACCACTATAG-CTGCCGGA-30-TAMRA, respectively [24].

2.9. Statistical Analysis. Data are presented as mean \pm SE. Student's *t*-test was used to analyze differences in immune mediators (TNF- α , IL-2, IL-4, IL-10, IL-4, GM-CSF, and MCP-1 levels) and DENV viral load on the first and third postinfection days between the T2DM group and control groups. A *P* value of < 0.05 was considered statistically significant.

3. Results

3.1. Demographics, Clinical, and Laboratory Information of the Participants. A total of 33 T2DM individuals (mean glycosylated hemoglobin, $7.9 \pm 1.6 \text{ gm/dL}$) and 29 healthy individuals were recruited for this study. Participants with and without T2DM were of similar ages (mean age, 55.8 ± 2.4 years versus 54.6 ± 2.6 years; P = 0.083). Among the 33 T2DM participants, hypertension (63.6%) was the most common comorbidity, followed by ischemic heart disease (9.1%) and previous stroke (6.1%). All participants were negative for dengue antibody as determined by dengue blot detection kit suggesting that none of them had suffered dengue before participating in this study.

3.2. Comparison of TNF- α , IL-2, IL-4, IL-10, IL-12, GM-CSF, and MCP-1 Levels between T2DM and Control Groups on the First and Third Postinfection Days. On the first postinfection day, no significant difference was found in concentrations of TNF- α , IL-2, IL-10, IL-12, GM-CSF, and MCP-1 between the T2DM group and control group, but significantly higher IL-4 level (mean 1.02 ± 0.2 pg/mL versus 0.52 ± 0.13 pg/mL; *P* = 0.049) was detected in the T2DM group (Figure 1).

On the third postinfection day, the T2DM group had significantly higher IL-4 (mean 16.87 ± 4.96 pg/mL versus 4.13 ± 1.23 pg/mL; P = 0.022), IL-10 (mean 138.89 ± 34.62 pg/mL versus 55.49 ± 18.7 pg/mL; P = 0.046), and GM-CSF (mean 20.8 ± 5.3 pg/mL versus 5.1 ± 1.46 pg/mL; P = 0.009) levels than those of the control group. Despite nonstatistical significance, there was a trend suggesting possible higher level of vascular leakage mediator MCP-1

(mean MCP-1, 4739.75 \pm 655.6 pg/mL versus 3980.8 \pm 639.29 pg/mL; P = 0.413) in the T2DM group (Figure 2).

3.3. DENV Viral Load of T2DM and Control Groups. Viral load was not detected in 1 of the specimens in T2DM group on the first and third postinfection days and in 2 and 3 specimens in the control group on the first and third postinfection days, respectively. No significant difference in detectable DENV viral load between the cultured mononuclear cells from both groups was found on the first and third postinfection days (Figure 3).

4. Discussion

DM was found to be one of the many epidemiologically identified risk factors for developing severe dengue/DHF in dengue affected patients [10-13, 35]. Most of the published researches in immunology in dengue involved general population rather than a population with specific underlying disease(s) [36]. When it comes to immunopathogenesis, the role of viral burden has been controversial in DHF [21, 37, 38]. Among the multifaceted mechanism of pathogenesis of dengue, high DENV burden was reported to circumstantially associate with DHF in hosts with secondary infection [37, 38], while the overwhelming activation of Th2 cytokines was documented in the development of DHF in dengue patients of primary and secondary infections alike [17, 20-24]. Specifically, of the Th2 cytokine profile, IL-4 is the most potent cytokine in inducing Th2 cell differentiation, whereas IL-10 is responsible for anti-inflammatory reactions in the host's immune activities [21–23, 31, 36]. A significantly higher level of IL-4 found on the first postinfection day, as well as higher levels of IL-4 and IL-10 detected on the third postinfection day in the T2DM group as compared to the control group, suggests that dengue patients with an underlying T2DM are at higher risk for development of DHF, which was consistent with the same conclusion drawn based on previous epidemiological observations [10–13].

A number of proinflammatory cytokines/chemokines including TNF- α , IL-1 and IL-6, and MCP-1 were well documented to involve in the pathogenesis of diabetes mellitus [39]. GM-CSF stimulates stem cells to produce granulocytes and monocytes and plays an important role in the immune/inflammatory cascade [40]. It was reported that serum GM-CSF was significantly raised in patients with severe dengue as compared to those with mild-form dengue, and the increased GM-CSF level correlated with the development of hypotension in DHF patients [41]. The increased production of the IL-4 and the anti-inflammatory Th2-cytokine IL-10 in DENV-infected mononuclear cells of the diabetes in our study might result from a counterbalance to the comparatively highly produced pro-inflammatory cytokines/chemokines in the diabetic hosts [18, 19].

Limitations of this study are that the included patients were adults with a T2DM suffering from primary dengue infection, and therefore, it is uncertain whether similar immunologic responses occur in pediatric patients, in patients with type 1 DM, and/or in those with secondary dengue infection.



FIGURE 1: Cytokines/chemokines produced by dengue virus-infected mononuclear cells of T2DM group and control group on the first postinfection day in an *in vitro* infection model.



FIGURE 2: Cytokines/chemokines produced by dengue virus-infected mononuclear cells of T2DM group and control group on the third postinfection day in an *in vitro* infection model.



FIGURE 3: Dengue viral load in the infected mononuclear cells of T2DM group and control group on the first (a) and third (b) postinfection days in an *in vitro* infection model.

In summary, this study explored the immunologic reactions in adults with T2DM experiencing primary dengue infection, and our data give insight into the immunopathogenesis of dengue in this patient population. The immunological findings suggest that patients T2DM are at higher risk for development of DHF and strengthen the previously epidemiologically identified role of DM being a predictive risk factor for progressing into DHF/severe dengue in dengue-affected patients. Stratifications of clinical severity and prediction of the risk for potential clinical deterioration are very important in a large-scale dengue epidemic happening in rural areas where medical resources are deficient, as strict observation is needed for the identified potentially risky patients so that necessary management can be delivered in a timely fashion in case of deterioration.

Acknowledgments

This study was supported by the Grants from the National Science Council, Executive Yuan, Taiwan (NSC100-2314-B-182-002-MY3 and NSC100-2314-B-037-001-MY3), and a Grant from Kaohsiung Chang Gung Memorial Hospital, Taiwan (CMRPG890321).

References

- World Health Organization, *Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control*, World Health Organization, Geneva, Switzerland, 2009.
- [2] C. P. Simmons, J. J. Farrar, N. van Vinh Chau, and B. Wills, "Current concepts: Dengue," *The New England Journal of Medicine*, vol. 366, no. 15, pp. 1423–1432, 2012.
- [3] S. B. Halstead, "Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion," *Yale Journal* of Biology and Medicine, vol. 42, no. 5, pp. 350–362, 1970.

- [4] D. M. Morens, "Antibody-dependent enhancement of infection and the pathogenesis of viral disease," *Clinical Infectious Diseases*, vol. 19, no. 3, pp. 500–512, 1994.
- [5] R. Rico-Hesse, L. M. Harrison, A. Nisalak et al., "Molecular evolution of dengue type 2 virus in Thailand," *American Journal* of *Tropical Medicine and Hygiene*, vol. 58, no. 1, pp. 96–101, 1998.
- [6] B. D. Pandey and A. Igarashi, "Severity-related molecular differences among nineteen strains of dengue type 2 viruses," *Microbiology and Immunology*, vol. 44, no. 3, pp. 179–188, 2000.
- [7] N. T. Lan and K. Hirayama, "Host genetic susceptibility to severe dengue infection," *Tropical Medicine and International Health*, vol. 39, supplement 4, pp. 73–81, 2011.
- [8] I.-K. Lee, J.-W. Liu, and K. D. Yang, "Clinical and laboratory characteristics and risk factors for fatality in elderly patients with dengue hemorrhagic fever," *American Journal of Tropical Medicine and Hygiene*, vol. 79, no. 2, pp. 149–153, 2008.
- [9] M. G. Guzmán, G. Kouri, J. Bravo, L. Valdes, V. Susana, and S. B. Halstead, "Effect of age on outcome of secondary dengue 2 infections," *International Journal of Infectious Diseases*, vol. 6, no. 2, pp. 118–124, 2002.
- [10] J. Pang, A. Salim, V. J. Lee et al., "Diabetes with hypertension as risk factors for adult dengue hemorrhagic fever in a predominantly dengue serotype 2 epidemic: a case control study," *PLoS Neglected Tropical Diseases*, vol. 6, no. 5, article e1641, 2012.
- [11] M. A. Figueiredo, L. C. Rodrigues, M. L. Barreto et al., "Allergies and diabetes as risk factors for dengue hemorrhagic fever: results of a case control study," *PLoS Neglected Tropical Diseases*, vol. 4, no. 6, article e699, 2010.
- [12] D. Limonta, G. Torres, V. Capó, and M. G. Guzmán, "Apoptosis, vascular leakage and increased risk of severe dengue in a type 2 diabetes mellitus patient," *Diabetes and Vascular Disease Research*, vol. 5, no. 3, pp. 213–214, 2008.
- [13] J. R. Bravo, M. G. Guzmán, and G. P. Kouri, "Why dengue haemorrhagic fever in Cuba? I. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS)," *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 81, no. 5, pp. 816–820, 1987.

- [14] I. Conget, "Diagnosis, classification and pathogenesis of diabetes mellitus," *Revista Española de Cardiologia*, vol. 55, no. 5, pp. 528–535, 2002.
- [15] T. Benfield, J. S. Jensen, and B. G. Nordestgaard, "Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome," *Diabetologia*, vol. 50, no. 3, pp. 549–554, 2007.
- [16] M. Stolar, "Glycemic control and complications in type 2 diabetes mellitus," *American Journal of Medicine*, vol. 123, no. 3, pp. S3–S11, 2010.
- [17] U. C. Chaturvedi, R. Agarwal, E. A. Elbishbishi, and A. S. Mustafa, "Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis," *FEMS Immunology and Medical Microbiology*, vol. 28, no. 3, pp. 183–188, 2000.
- [18] S. Nakayamada, H. Takahashi, Y. Kanno, and J. J. O'Shea, "Helper T cell diversity and plasticity," *Current Opinion in Immunology*, vol. 24, no. 3, pp. 297–302, 2012.
- [19] T. R. Mosmann and S. Sad, "The expanding universe of T-cell subsets: Th1, Th2 and more," *Immunology Today*, vol. 17, no. 3, pp. 138–146, 1996.
- [20] U. C. Chaturvedi, E. A. Elbishbishi, R. Agarwal et al., "Sequential production of cytokines by dengue virus-infected human peripheral blood leukocyte cultures," *Journal of Medical Virol*ogy, vol. 59, no. 3, pp. 335–340, 1999.
- [21] R.-F. Chen, J.-W. Liu, W.-T. Yeh et al., "Altered T helper 1 reaction but not increase of virus load in patients with dengue hemorrhagic fever," *FEMS Immunology and Medical Microbiology*, vol. 44, no. 1, pp. 43–50, 2005.
- [22] R.-F. Chen, K. D. Yang, L. Wang, J.-W. Liu, C.-C. Chiu, and J.-T. Cheng, "Different clinical and laboratory manifestations between dengue haemorrhagic fever and dengue fever with bleeding tendency," *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 101, no. 11, pp. 1106–1113, 2007.
- [23] S. Green, D. W. Vaughn, S. Kalayanarooj et al., "Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity," *Journal of Medical Virology*, vol. 59, no. 3, pp. 329–334, 1999.
- [24] W.-T. Yeh, R.-F. Chen, L. Wang, J.-W. Liu, M.-F. Shaio, and K. D. Yang, "Implications of previous subclinical dengue infection but not virus load in dengue hemorrhagic fever," *FEMS Immunology and Medical Microbiology*, vol. 48, no. 1, pp. 84–90, 2006.
- [25] J. Groen, P. Koraka, J. Velzing, C. Copra, and A. D. M. E. Osterhaus, "Evaluation of six immunoassays for detection of dengue virus-specific immunoglobulin M and G antibodies," *Clinical and Diagnostic Laboratory Immunology*, vol. 7, no. 6, pp. 867–871, 2000.
- [26] R.-F. Chen, W.-T. Yeh, M.-Y. Yang, and K. D. Yang, "A model of the real-time correlation of viral titers with immune reactions in antibody-dependent enhancement of dengue-2 infections," *FEMS Immunology and Medical Microbiology*, vol. 30, no. 1, pp. 1–7, 2001.
- [27] K. D. Yang, C.-L. Wang, and M.-F. Shaio, "Production of cytokines and platelet activating factor in secondary dengue virus infections," *Journal of Infectious Diseases*, vol. 172, no. 2, pp. 604–605, 1995.
- [28] D. R. Palmer, P. Sun, C. Celluzzi et al., "Differential effects of dengue virus on infected and bystander dendritic cells," *Journal* of Virology, vol. 79, no. 4, pp. 2432–2439, 2005.
- [29] T.-H. Chang, S.-R. Chen, C.-Y. Yu et al., "Dengue virus serotype 2 blocks extracellular signal-regulated kinase and nuclear factor-κB activation to downregulate cytokine production," *PLoS One*, vol. 7, no. 8, article e41635, 2012.

- [30] D. H. Libraty, S. Pichyangkul, C. Ajariyakhajorn, T. P. Endy, and F. A. Ennis, "Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis," *Journal of Virology*, vol. 75, no. 8, pp. 3501–3508, 2001.
- [31] I. Kurane, "Dengue hemorrhagic fever with special emphasis on immunopathogenesis," *Comparative Immunology, Microbiology* and Infectious Diseases, vol. 30, no. 5-6, pp. 329–340, 2007.
- [32] Y.-R. Lee, M.-T. Liu, H.-Y. Lei et al., "MCPI, a highly expressed chemokine in dengue haemorrhagic fever/dengue shock syndrome patients, may cause permeability change, possibly through reduced tight junctions of vascular endothelium cells," *Journal of General Virology*, vol. 87, no. 12, pp. 3623–3630, 2006.
- [33] S. Bernasconi, C. Matteucci, M. Sironi et al., "Effects of granulocyte-monocyte colony-stimulating factor (GM-CSF) on expression of adhesion molecules and production of cytokines in blood monocytes and ovarian cancer-associated macrophages," *International Journal of Cancer*, vol. 60, no. 3, pp. 300–307, 1995.
- [34] K. G. Oliver, J. R. Kettman, and R. J. Fulton, "Multiplexed analysis of human cytokines by use of the flowmetrix system," *Clinical Chemistry*, vol. 44, no. 9, pp. 2057–2060, 1998.
- [35] C.-Y. Tsai, I.-K. Lee, C.-H. Lee, K. D. Yang, and J.-W. Liu, "Comparisons of dengue illness classified based on the 1997 and 2009 World Health Organization dengue classification schemes," *Journal of Microbiology, Immunology and Infection*, vol. 46, no. 4, pp. 271–281, 2013.
- [36] B. Spellberg and J. E. Edwards Jr., "Type 1/type 2 immunity in infectious diseases," *Clinical Infectious Diseases*, vol. 32, no. 1, pp. 76–102, 2001.
- [37] D. H. Libraty, T. P. Endy, H.-S. H. Houng et al., "Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections," *Journal of Infectious Diseases*, vol. 185, no. 9, pp. 1213–1221, 2002.
- [38] W.-K. Wang, D.-Y. Chao, C.-L. Kao et al., "High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis," *Virology*, vol. 305, no. 2, pp. 330–338, 2003.
- [39] H. Tilg and A. R. Moschen, "Inflammatory mechanisms in the regulation of insulin resistance," *Molecular Medicine*, vol. 14, no. 3-4, pp. 222–231, 2008.
- [40] S. Bernasconi, C. Matteucci, M. Sironi et al., "Effects of granulocyte-monocyte colony-stimulating factor (GM-CSF) on expression of adhesion molecules and production of cytokines in blood monocytes and ovarian cancer-associated macrophages," *International Journal of Cancer*, vol. 60, no. 3, pp. 300–307, 1995.
- [41] F. A. Bozza, O. G. Cruz, S. M. Zagne et al., "Multiplex cytokine profile from dengue patients: MIP-lbeta and IFN-gamma as predictive factors for severity," *BMC Infectious Diseases*, vol. 8, article 86, 2008.